. 2019 Sep 12;48:332–340. doi: 10.1016/j.ebiom.2019.08.059

Table 1.

Patient demographics, tumor properties and outcome of patients included for model building.

Institution		TUM training	UW validation	p-Values^a
Total patients		122 p	103 p
Location	Extremity or trunk	115/122 p	99/103 p	1
	Extremity or trunk	(94%)	(96%)	1
	Abdomen/retroperitoneal	7/122 p	4/103 p
	Abdomen/retroperitoneal	(6%)	(4%)
Age		m 57 (sd: 16.7)	m 52.7 (sd:15.5)	.2
Gender	Female	57/122 p	47/103 p	1
	Female	(47%)	(46%)	1
	Male	65/122 p	56/103 p
	Male	(53%)	(54%)
T-stage^b	1	18/122 p	17/103 p	1
	1	(15%)	(17%)	1
	2	104/122 p	86/103 p
	2	(85%)	(83%)
	a	11/122 p	1/103 p	1
	a	(9%)	(1%)	1
	b	111/122 p	102/103 p
	b	(91%)	(99%)
M-stage^b	0	117/122 p	102/103 p	1
	0	(96%)	(99%)	1
	1	5/122 p	1/103 p
	1	(4%)	(1%)
N-stage^b	0	120/122 p	103/103 p (100%)	1
	0	(98.0%)	103/103 p (100%)	1
	1	2/122 p	0/103 p
	1	(2%)	(0%)
Grading^c	1	48/122 p	20/103 p (19.5%)	.05
	1	(4.8%)	20/103 p (19.5%)	.05
	2	28/122 p (32.1%)	31/103 p (32.2%)
	3	46/122 p (46.4%)	52/103 p (48.3%)
Tumor volume		197.6 cc	164.5 cc
Tumor volume		(sd: 391.4)	(sd: 428.8)
AJCC-stage	IA	8/122 p	4/103 p	p < .001
	IA	(7%)	(4%)	p < .001
	IB	40/122 p	16/103 p
	IB	(33%)	(16%)
	IIA	8/122 p	13/103 p
	IIA	(7%)	(13%)
	IIB	5/122 p	23/103 p
	IIB	(4%)	(22%)
	III	57/122 p	47/103 p
	III	(47%)	(46%)
	IV	4/122 p	0/103 p
	IV	(3%)	(0%)
Median OS		35.7 mo	44.7 mo	.2

Abbreviations: cc: cubic centimeters, m: median, mo: months, p: patients, TUM: Technical University of Munich, UW: University of Washington, sd: standard deviation.

Categorial variables: Fisher’ exact test (2 cohorts)) and continuous/Rank variables: Wilcoxon rank sum test (2 cohorts), log-rank test for survival, with bonferroni correction for multiple testing.

Following AJCC staging system version 7 [36].

According to French Federation of Cancer Centers Sarcoma Group (FFCCS) [5].